Volume 8, Issue 4 (7-2017)                   Caspian J Intern Med 2017, 8(4): 228-238 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saburi E, Saburi A, Ghanei M. Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside . Caspian J Intern Med 2017; 8 (4) :228-238
URL: http://caspjim.com/article-1-847-en.html
Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside
Ehsan Saburi , Amin Saburi , Mostafa Ghanei *
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran , mghaneister@gmail.com
Abstract:   (10681 Views)

Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.

Keywords: Cancer, Immunotherapy, Macrophage activating factor, GC-MAF, Vitamin D.
Full-Text [PDF 548 kb]   (2279 Downloads)    
Type of Study: Review Article | Subject: Oncology
Received: 2016/08/22 | Accepted: 2017/03/6 | Published: 2017/07/29
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by: Yektaweb